Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results From the Phase II Dose-Ranging Study, Pride-HD
Objective: To assess efficacy, safety, and tolerability of multiple doses of pridopidine in HD patients (pts) with signs of motor dysfunction. Background: Prior trials suggested…Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson’s Disease Reduces the Risk of Polypharmacy: Five-Year Analysis
Objective: To compare the proportion of subjects on polypharmacy after five years in the deep brain stimulation (DBS) in early stage Parkinson’s disease (PD) pilot…Disease-modification in Translational Models of Parkinson’s disease by the Rho Kinase Inhibitor Fasudil
Objective: To evaluate the therapeutic potential of the Rho Kinase (ROCK) inhibitor Fasudil in translational models of Parkinson’s disease (PD). Background: There is still a…Medical Treatment Termination in Parkinson’s Disease Patients after Hepad Therapy: A Case Series
Objective: To report seven clinical cases of treatment completion and improvement of symptoms after a PD therapy regimen that included Hepad. Background: DOPA decarboxylase inhibitor…The influence of neurorehabilitation on Parkinson medication
Objective: To investigate the influence of neurorehabilitation on the dose changes of Parkinson medication over time. Background: In progressive disorders such as Parkinson’s disease (PD),…Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson’s disease patients: Dosing patterns
Objective: Describe the dosing patterns in advanced Parkinson's disease (PD) patients who completed conversion to IPX066 from other levodopa formulations. Background: IPX066 is an extended-release…Critical path for Parkinson’s II: Global regulatory agencies support the use of dopamine transporter neuroimaging as an enrichment biomarker to enable clinical trials in early Parkinson’s disease
Objective: This presentation focuses on neuroimaging of the Dopamine Transporter as an enrichment biomarker in clinical trials of Parkinson's disease (PD). Background: The Critical Path…Conversion of patients from immediate release carbidopa-levodopa (IR CD-LD) and sustained release carbidopa-levodopa (SR CD-LD) to extended-release carbidopa-levodopa (ER CD-LD) in clinical practice
Objective: To evaluate the real-world response of patients who are converted from IR CD-LD and SR CD-LD to ER CD-LD in an academic practice. Background:…Lessons-experienced in the creation of a global public-private consortium with the goal of advancing treatments that hold most potential for delayed disease progression in Parkinson’s disease – Critical path for Parkinson’s (CPP)
Objective: The path is summarized that led to the creation of a global public-private-partnership uniting an international non-profit charity, Parkinson's UK, a global non-profit organization,…Extended-release carbidopa-levodopa, IPX066: Dosing and efficacy with concomitant medication use in Parkinson’s disease
Objective: Evaluate the efficacy and dosing of IPX066 in patient groups taking concomitant Parkinson's disease (PD) medication, using post hoc subgroup analyses. Background: IPX066 is…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- 32
- Next Page »